EPG-HU1418-201 (Advarra IRB)

Who Can Participate in the Study?

Age Group
Children

Study Details

Full Title
EPG-HU1418-201: A Phase 2/3 Study to Characterize and Evaluate the Efficacy, Safety, and Tolerability of hu14.18K322A Treatment Given in Combination with Chemotherapy in Participants with High-Risk Neuroblastoma
Principal Investigator
Headshot of Jessica Muller Sun
Associate Professor of Pediatrics
Protocol Number
IRB: PRO00119566
NCT: NCT07549321
Phase
Phase II/III
ClinicalTrials.gov
Status
OPEN TO ACCRUAL